Woodline Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Woodline Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.7M	Buy	140,288 +5,334	+4%	+$2.36M	0.22%	114
2026 Q1	$60.3M	Buy	134,954 +7,228	+6%	+$3.37M	0.23%	107
2025 Q4	$57.9M	Sell	127,726 -25,546	-17%	-$11M	0.22%	106
2025 Q3	$60M	Buy	153,272 +61,608	+67%	+$25.7M	0.28%	80
2025 Q2	$40.8M	Sell	91,664 -61,496	-40%	-$28.3M	0.22%	133
2025 Q1	$74.3M	Buy	153,160 +3,742	+3%	+$1.74M	0.48%	32
2024 Q4	$60.2M	Buy	149,418 +16,653	+13%	+$7.72M	0.41%	57
2024 Q3	$61.7M	Buy	+132,765	New	+$63.8M	0.52%	43
2024 Q1	–	Sell	-2,742	Closed	-$1.12M	–	643
2023 Q4	$1.12M	Buy	+2,742	New	+$1.01M	0.01%	401
2022 Q2	–	Sell	-74,671	Closed	-$19.5M	–	896
2022 Q1	$19.5M	Sell	74,671 -29,109	-28%	-$6.91M	0.32%	96
2021 Q4	$22.8M	Buy	103,780 +23,293	+29%	+$4.53M	0.33%	75
2021 Q3	$14.6M	Sell	80,487 -83,577	-51%	-$16.3M	0.24%	118
2021 Q2	$33.1M	Sell	164,064 -50,012	-23%	-$10.5M	0.62%	41
2021 Q1	$46M	Buy	+214,076	New	+$47M	1.02%	19

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Woodline Partners's VRTX Position: Q2 2026 in Review

Woodline Partners increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, buying an estimated $2.36M and bringing the position to 140,288 shares worth $69.7M. The position accounts for 0.22% of the portfolio, ranked #114.

Woodline Partners first reported a position in VRTX in Q1 2021 and has held it in 14 quarters since. The position peaked at $74.3M in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Woodline Partners held 140,288 shares of Vertex Pharmaceuticals worth $69.7M as of Q2 2026.
Woodline Partners bought 5,334 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.36M.
Vertex Pharmaceuticals made up 0.22% of Woodline Partners's portfolio in Q2 2026, its #114 holding.
Woodline Partners first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
Woodline Partners's Vertex Pharmaceuticals position peaked at $74.3M in Q1 2025.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.